Cancer immunotherapy

Definition

Cancer immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system. Some cancer immunotherapies consist of antibodies that bind to, and inhibit the function of, proteins expressed by cancer cells. Other cancer immunotherapies include vaccines and T cell infusions.

Featured

Latest Research and Reviews

  • Research |

    Vijayanand and colleagues use genome-wide RNA sequencing for transcriptional profiling of CD8+ T cells from tumors and adjacent uninvolved lung tissue from patients with early-stage lung cancer. A tissue-resident memory signature is associated with enhanced cytotoxicity and improved survival.

    • Anusha-Preethi Ganesan
    • , James Clarke
    • , Oliver Wood
    • , Eva M Garrido-Martin
    • , Serena J Chee
    • , Toby Mellows
    • , Daniela Samaniego-Castruita
    • , Divya Singh
    • , Grégory Seumois
    • , Aiman Alzetani
    • , Edwin Woo
    • , Peter S Friedmann
    • , Emma V King
    • , Gareth J Thomas
    • , Tilman Sanchez-Elsner
    • , Pandurangan Vijayanand
    •  & Christian H Ottensmeier
  • Research | | open

    Trex1 is an exonuclease that degrades cytosolic DNA and has been associated with modulation of interferon responses in autoimmunity and viral infections. Here, the authors show that Trex1 attenuates the immunogenicity of cancer cells treated with high radiation doses by degrading cytosolic DNA and preventing the activation of interferon response.

    • Claire Vanpouille-Box
    • , Amandine Alard
    • , Molykutty J. Aryankalayil
    • , Yasmeen Sarfraz
    • , Julie M. Diamond
    • , Robert J. Schneider
    • , Giorgio Inghirami
    • , C. Norman Coleman
    • , Silvia C. Formenti
    •  & Sandra Demaria
  • Research | | open

    Loss of major histocompatibility complex MHC-I expression contributes to cancer immune evasion. Here, the authors show that, in both mice and humans, MHC-I downregulation is associated with the induction of NK-cell exhaustion and that IL-21 restores NK-cell function and inhibits tumours progression.

    • Hyungseok Seo
    • , Insu Jeon
    • , Byung-Seok Kim
    • , Myunghwan Park
    • , Eun-Ah Bae
    • , Boyeong Song
    • , Choong-Hyun Koh
    • , Kwang-Soo Shin
    • , Il-Kyu Kim
    • , Kiyoung Choi
    • , Taegwon Oh
    • , Jiyoun Min
    • , Byung Soh Min
    • , Yoon Dae Han
    • , Suk-Jo Kang
    • , Sang Joon Shin
    • , Yeonseok Chung
    •  & Chang-Yuil Kang
  • Reviews |

    In recent years, the molecular characterization of gastric adenocarcinoma — the most common stomach cancer — has identified numerous targets for potential exploitation into therapy. However, advances are still lagging compared with other cancers of similar incidence. In this Primer, Ajani et al. describe these advances and the work still needed to be done.

    • Jaffer A. Ajani
    • , Jeeyun Lee
    • , Takeshi Sano
    • , Yelena Y. Janjigian
    • , Daiming Fan
    •  & Shumei Song

News and Comment